In briefBMJ 2003; 326 doi: http://dx.doi.org/10.1136/bmj.326.7396.948 (Published 03 May 2003) Cite this as: BMJ 2003;326:948
GlaxoSmithKline slashes cost of AIDS drug: GlaxoSmithKline is to reduce the cost of its antiretroviral drug Combivir (zidovudine and lamivudine) by almost half to $0.90 (£0.57; a0.82) a day in 63 developing countries. The company's move comes after pressure from the company's institutional investors to make access to AIDS drugs easier.
US sugar industry pressurises …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial